Recent Price Moves Put Immunocore Holdings in Focus

Immunocore Holdings (IMCR) has drawn fresh attention after a recent share price move, with the stock last closing at $30.88. That shift, combined with mixed short and longer term returns, has prompted closer scrutiny.

The recent 1 week share price return of 5.21% and 1 month share price return of 6.89% contrasts with a year to date share price decline of 8.58% and a 3 year total shareholder return that declined 47.27%. This suggests improving short term momentum after a challenging period for Immunocore Holdings investors.

If Immunocore Holdings has caught your attention, it can help to see what else is moving in similar areas of the market. You can start with 40 healthcare AI stocks

With Immunocore Holdings trading at $30.88, carrying a value score of 4 and a reported intrinsic discount of 87.11%, the key question is whether the stock is genuinely undervalued or whether the market is already pricing in future growth.

Most Popular Narrative: 53.6% Undervalued

The most followed narrative on Immunocore Holdings pegs fair value at $66.57 versus the last close at $30.88, framing a wide valuation gap and centering attention on future earnings power and cash flows.

Significant cash balance ($883 million) and disciplined SG&A spend provide Immunocore with the resources and strategic flexibility to advance its clinical portfolio and capitalize on long-term industry trends, supporting revenue growth and potential positive net margins in the future.

There is a clear earnings story behind that $66.57 fair value. It leans on robust top line expansion, a margin shift, and a valuation multiple usually reserved for faster growing sectors. Curious which assumptions have to line up for that gap to close? The full narrative lays out the numbers and timing in detail.

Result: Fair Value of $66.57 (UNDERVALUED)

However, Immunocore Holdings still leans heavily on KIMMTRAK and faces higher R&D spending, so any clinical setback or weaker uptake could quickly challenge this positive case.

Another View On Immunocore Holdings Valuation

The earlier fair value work based on future earnings and P/E points to Immunocore Holdings looking undervalued. On the other hand, its current P/S of 3.8x sits above a fair ratio of 3.1x, while still below the US Biotechs average of 11.8x. This hints at both upside potential and valuation risk if sentiment cools.

For a closer look at what this gap between current P/S, peers, and the fair ratio might mean in practice, including where the market could move if expectations reset, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment mixed across Immunocore Holdings, it helps to move quickly and check the underlying data yourself before forming a view. To see what investors are optimistic about in the current setup, review the 2 key rewards

Looking For More Investment Ideas Beyond Immunocore Holdings?

If Immunocore Holdings has sharpened your focus, do not stop here. Broaden your watchlist with other ideas that could suit different goals and risk levels.

• Spot potential future standouts early by checking the screener containing 19 high quality undiscovered gems before they attract wider attention.
• Strengthen your portfolio’s foundation by using the solid balance sheet and fundamentals stocks screener (48 results) to zero in on companies with sturdier financial footing.
• Build a steadier income stream by reviewing the 8 dividend fortresses that combine higher yields with an emphasis on resilience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.